Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1696945 | 0.80 | USP2 (0.55) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL246985 | 0.80 | USP2 (0.55) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL27661966 | 0.73 | USP2 (0.33) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL5436780 | 0.72 | USP2 (0.65) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL8803522 | 0.72 | USP2 (0.64) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL9064623 | 0.71 | USP2 (0.53) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL9064886 | 0.71 | USP2 (0.53) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL9065107 | 0.71 | USP2 (0.53) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL14938558 | 0.70 | USP2 (0.57) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL7263034 | 0.70 | USP2 (0.57) | USP2SLCO1B1LMNAL3MBTL1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456546-A | Liposomal compositions for mucosal delivery | 葛兰素史密丝克莱恩生物有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106893724-B | Oligonucleotide with antigen synergism and tumor treatment effect | 苏州派动生物技术有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11081235-B2 | Extracellular matrix metalloproteinase inducer (EMMPRIN) peptides and binding antibodies | MOR-RESEARCH APPLICATIONS LTD. (IL) | 2021-08-03 | — | — | US | disclosed |
| US-20190309031-A1 | EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) PEPTIDES AND BINDING ANTIBODIES | MOR - RESEARCH APPLICATIONS LTD. (IL) | 2019-10-10 | — | — | US | disclosed |
| US-10426828-B2 | Compositions of multimeric-multiepitope influenza polypeptides and their production | BIONDVAX PHARMACEUTICALS LTD. (IL) | 2019-10-01 | — | — | US | disclosed |
| CN-110229813-A | Oligonucleotides with vaccine adjuvant effect and oncotherapy effect | 苏州派动生物技术有限公司 | 2019-09-13 | — | — | CN | disclosed |
| EP-3492095-A1 | EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) PEPTIDES AND BINDING ANTIBODIES | Technion Research & Development Foundation Limited (IL) | 2019-06-05 | — | — | EP | disclosed |
| US-20180318415-A1 | NOVEL ADJUVANT FORMULATIONS | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2018-11-08 | — | — | US | disclosed |
| EP-3386540-A1 | NOVEL ADJUVANT FORMULATIONS | GlaxoSmithKline Biologicals S.A. (BE) | 2018-10-17 | — | — | EP | disclosed |
| EP-2833900-B1 | EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) PEPTIDES AND BINDING ANTIBODIES | TECHNION RES & DEV FOUNDATION (IL) | 2018-09-19 | — | — | EP | disclosed |
| EP-0983286-B1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORP (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20040029279-A1 | Packaging of positive-strand rna virus replicon particles | WYETH HOLDINGS CORPORATION | 2004-02-12 | — | — | US | disclosed |
| US-20030198645-A1 | Vaccines; stimulant of lymphocytes against hepatatis; induce immunology response | APOVIA INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1326990-A2 | PACKAGING OF POSITIVE-STRAND RNA VIRUS REPLICON PARTICLES | Wyeth Holdings Corporation (US) | 2003-07-16 | — | — | EP | disclosed |
| US-6355257-B1 | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2002-03-12 | — | — | US | disclosed |
| WO-2002018585-A2 | PACKAGING OF POSITIVE-STRAND RNA VIRUS REPLICON PARTICLES | WYETH HOLDINGS CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
| US-6113918-A | IMMUNOLOGY | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| CN-1265112-A | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors | KRIKSA LTD (US) | 2000-08-30 | — | — | CN | disclosed |
| EP-0983286-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11081235-B2 | Extracellular matrix metalloproteinase inducer (EMMPRIN) peptides and binding antibodies | BSG, MMP7, CD14 | USP2 4540/4885SLCO1B1 2954/4885LMNA 1793/4885 |
| US-20180318415-A1 | NOVEL ADJUVANT FORMULATIONS | LGALS3BP, LGALS2, LGALS4 | USP2 2366/4885SLCO1B1 1863/4885LMNA 4801/4885 |
| US-20190309031-A1 | EXTRACELLULAR MATRIX METALLOPROTEINASE INDUCER (EMMPRIN) PEPTIDES AND BINDING ANTIBODIES | BSG, MMP7, CD14 | USP2 4540/4885SLCO1B1 2954/4885LMNA 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.